You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

33 Items
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
New
Nov 2019
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
New
Nov 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
Exceptional Access Program
    lenalidomide - Treatment of multiple myeloma in combination with dexamethasone in patients who are not candidates
    for autologous stem cell transplant, with specific criteria
ODB - General Benefit
    dexamethasone
Oct 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Carfilzomib (Triplet Therapy) - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    lenalidomide - In combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma
Oct 2019
Cancer Type: Hematologic, Leukemia - Hairy Cell, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Jan 2018
Cancer Type: Hematologic, Leukemia - Hairy Cell, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Maintenance Treatment - Lymphoma
Jul 2019
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
New
Nov 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Oct 2017
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    dexamethasone
Sep 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab – In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    lenalidomide - For the treatment of patients with multiple myeloma with good performance status who have received at least one prior therapy.
Jul 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Drugs Used:
ixazomib (Unfunded),
lenalidomide (Unfunded),
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
Exceptional Access Program
    lenalidomide - Treatment of multiple myeloma in combination with dexamethasone in patients who are not candidates
    for autologous stem cell transplant, with specific criteria
ODB - General Benefit
    dexamethasone
Aug 2019